In oncology, oral BCAA formulations have been given to patients with advanced liver cirrhosis (who often develop HCC)—some studies report improved survival and lower HCC recurrence, attributed to better liver function and possibly an anti-tumor milieu due to improved insulin sensitivity and reduced inflammation [117]. Here, INS is linked to hepatocellular carcinoma.